Catalyst

Slingshot members are tracking this event:

Exelixis (EXEL) and Bristol-Myers Squibb (BMY) to Present Phase 1b Data on Cobimetinib + Vemurafenib + Atezolizumab in Previously Untreated BRAF V600 Mutation-Positive Advanced Melanoma Monday October 10th

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
Importance
High Medium Low
Impact on Stocks
BMY

100%
EXEL

100%

Additional Information

http://www.esmo.org/...
Slingshot Insights Explained
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords European Society For Medical Oncology 2016, Cobimentinib, Vemurafenib, Atezolizumab, Previously Untreated Braf V600, Mutation-positive Advanced Melanoma